EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan

Johanne Skovgaard Schovsbo, PhD Student, Department of Haematology, Rigshospitalet, Copenhagen, Denmark, presents results at the EHA 2026 Congress comparing standard- and reduced-dose treosulfan conditioning before allogeneic hematopoietic cell transplantation. Despite being older and having a higher comorbidity burden, patients receiving reduced-dose treosulfan had similar overall survival, relapse risk, non-relapse mortality, and graft-versus-host disease outcomes.